ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026
Temporal Trends and Predictors of P2Y12 Inhibitor Selection and Switching Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients.
Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard care after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). While ticagrelor provides potent ischemic protection, bleeding risk, tolerability, and treatment access may influence real-world P2Y12 inhibitor selection and ticagrelor-to-clopidogrel switching. Contemporary data describing P2Y12 inhibitor selection and recorded switching patterns across ACS subtypes remain limited.
methodsWe conducted a retrospective cohort study using the TriNetX electronic health record database to identify adults hospitalized with ACS who underwent PCI between 2013 and 2021. Patients initiating ticagrelor or clopidogrel within 14 days post-PCI were included and categorized by initial P2Y12 inhibitor. Temporal trends were assessed annually. Multivariable logistic regression identified predictors of ticagrelor initiation. Among ticagrelor initiators, switching to clopidogrel within 365 days was evaluated, including cumulative switching at prespecified landmark time points.
resultsAmong 57,619 patients, 38.2% initiated ticagrelor and 61.8% clopidogrel. Ticagrelor initiation increased over time but remained less common overall. Ticagrelor initiation was more likely among younger patients, males, those with ST-elevation myocardial infarction, drug-eluting stent use, lower bleeding risk, and lower comorbidity burden, with substantial geographic variation observed. Among ticagrelor initiators, 31.4% had a recorded switch to clopidogrel within 1 year. Observed cumulative switching was 17.0% at 30 days, 23.0% at 90 days, 26.8% at 180 days, and 31.4% at 365 days. The median time to switch was not estimable because fewer than 50% of patients switched during follow-up.
conclusionIn this real-world cohort of patients with ACS undergoing PCI, initial P2Y12 inhibitor selection varied by demographic, clinical, procedural, and geographic characteristics. Recorded ticagrelor-to-clopidogrel switching was common but should not be interpreted uniformly as intentional clinical de-escalation. These findings highlight the need for future research to clarify reasons for switching and to inform individualized P2Y12 inhibitor treatment strategies in routine practice.
Identifiers
42768140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.